HI
LCTX icon

Harbour Investments’s Lineage Cell Therapeutics LCTX Stock Holding History

Harbour Investments’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.1K Hold
1,600
– – ﹤0.01% 4006
2026
Q1 		$2.53K Hold
1,600
– – ﹤0.01% 3840
2025
Q4 		$2.67K Hold
1,600
– – ﹤0.01% 3230
2025
Q3 		$2.7K Hold
1,600
– – ﹤0.01% 3192
2025
Q2 		$1.45K Buy
+1,600
New +$949 ﹤0.01% 3210

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Harbour Investments's LCTX Position: Q2 2026 in Review

Harbour Investments held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 1,600 shares worth $2.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4006.

Harbour Investments first reported a position in LCTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.7K in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Harbour Investments held 1,600 shares of Lineage Cell Therapeutics worth $2.1K as of Q2 2026.
  • Harbour Investments left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4006 holding.
  • Harbour Investments first reported a position in Lineage Cell Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Harbour Investments's Lineage Cell Therapeutics position peaked at $2.7K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.